As 2018 drew to a close, we had a look at how many companies had been doing and what their prospects were for the new year. It’s hard to narrow it down, but we think these European biotechs are going to make headlines this year.
Last year was a great year for biotech in Europe. The list of biotech companies valued at more than €1B grew, and we saw some big acquisitions, including those of TiGenix and Ablynx.
This year appears as promising, with many companies expecting important results, starting critical clinical trials, and taking their business to a whole new level with recent big fundraising rounds. All of them would not fit in this list, so we asked several experts which biotech companies they expect to make the most noise in 2019. They are listed in no particular order.
Based in London, Orchard Therapeutics went directly into the European billion-euro club last October with an impressive IPO on the US Nasdaq. The company is developing gene therapies for inherited conditions that affect the immune system. With the money raised by its IPO, Orchard is planning to complete clinical development for its three lead gene therapy candidates and hopefully get them to the market.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed